Clostridium difficile 027/BI/NAP1 Encodes a Hypertoxic and Antigenically Variable Form of TcdB

PLoS Pathogens

Volumn 9, Issue 8, 2013, Pages

  Lanis, Jordi M ^a   Heinlen, Latisha D ^a   James, Judith A ^a,b   Ballard, Jimmy D ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL TOXIN; BACTERIAL TOXIN TCDB 003; BACTERIAL TOXIN TCDB 027; CLOSTRIDIUM DIFFICILE TOXOID 003; CLOSTRIDIUM DIFFICILE TOXOID 027; EPITOPE; TOXOID; UNCLASSIFIED DRUG; VIRULENCE FACTOR; BACTERIAL ANTIGEN; BACTERIAL PROTEIN; BACTERIUM ANTIBODY; NEUTRALIZING ANTIBODY; TOXB PROTEIN, CLOSTRIDIUM DIFFICILE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGENICITY; ARTICLE; BACTERIUM CULTURE; BRAIN HEMORRHAGE; CELL MEDIATED CYTOTOXICITY; CELL VIABILITY; CEREBELLUM; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; LETHAL DOSE; LETHALITY; MICROVASCULAR ENDOTHELIAL CELL; MOUSE; NONHUMAN; RABBIT; SURVIVAL RATE; ANIMAL; ANTIGENIC VARIATION; BAGG ALBINO MOUSE; CROSS REACTION; DISEASE MODEL; EPITOPE MAPPING; GENETICS; IMMUNOLOGY; PATHOGENICITY; PEPTOCLOSTRIDIUM DIFFICILE; PROTEIN TERTIARY STRUCTURE; PSEUDOMEMBRANOUS COLITIS;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODIES, NEUTRALIZING; ANTIGENIC VARIATION; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; BACTERIAL TOXINS; CLOSTRIDIUM DIFFICILE; CROSS REACTIONS; DISEASE MODELS, ANIMAL; ENTEROCOLITIS, PSEUDOMEMBRANOUS; EPITOPE MAPPING; EPITOPES; MICE, INBRED BALB C; PROTEIN STRUCTURE, TERTIARY;

EID: 84883438006     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1003523     Document Type: Article

References (70)

1. Bartlett JG, (1992) Antibiotic-associated diarrhea. Clin Infect Dis 15: 573-581.
2. McFarland LV, Mulligan ME, Kwok RYY, Stamm WE, (1989) Nosocomial acquisition of Clostridium difficile Infection. N Engl J Med 320: 204-210.
3. Gerding D, (2010) Global epidemiology of Clostridium difficile infection in 2010. Infect Control Hosp Epidemiol 31: S32-S34.
4. McDonald LC, Owings M, Jernigan DB, (2006) Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis 12: 409-415.
5. Bartlett JG, Moon N, Chang TW, Taylor N, Onderdonk AB, (1978) Role of Clostridium difficile in antibiotic-associated pseudomembranous colitis. Gastroenterology 75: 778-782.
6. Thibault A, Miller MA, Gaese C, (1991) Risk factors for the development of Clostridium difficile-associated diarrhea during a hospital outbreak. Infect Control Hosp Epidemiol 12: 345-348.
7. Fekety R, Shah AB, (1993) Diagnosis and treatment of Clostridium difficile colitis. JAMA 269: 71-75.
8. Bartlett JG, (2008) The case for vancomycin as the preferred drug for treatment of Clostridium difficile infection. Clin Infect Dis 46: 1489-1492.
9. Pepin J, Alary M-E, Valiquette L, Raiche E, Ruel J, et al. (2005) Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 40: 1591-1597.
10. Muto CA, Pokrywka M, Shutt K, Mendelsohn AB, Nouri K, et al. (2005) A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 26: 273-280.
11. Loo VG, Poirier L, Miller MA, Oughton M, Libman MD, et al. (2005) A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 353: 2442-2449.
12. McDonald LC, Killgore GE, Thompson A, Owens RC Jr, Kazakova SV, et al. (2005) An Epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 353: 2433-2441.
13. Warny M, Pepin J, Fang A, Killgore G, Thompson A, et al. (2005) Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 366: 1079-1084.
14. Kuntz JL, Chrischilles EA, Pendergast JF, Herwaldt LA, Polgreen PM, (2011) Incidence of and risk factors for community-associated Clostridium difficile infection: A nested case-control study. BMC Infect Dis 11: 194.
15. Khanna S, Pardi DS, Aronson SL, Kammer PP, Orenstein R, et al. (2012) The epidemiology of community-acquired Clostridium difficile infection: A population-based study. Am J Gastroenterol 107: 89-95.
16. Hubert B, Loo VG, Bourgault A-M, Poirier L, Dascal A, et al. (2007) A portrait of the geographic dissemination of the Clostridium difficile North American pulsed-field type 1 strain and the epidemiology of C. difficile-associated disease in Quebec. Clin Infect Dis 44: 238-244.
17. Karas JA, Enoch DA, Aliyu SH, (2010) A review of mortality due to Clostridium difficile infection. J Infect 61: 1-8.
18. Walk ST, Micic D, Jain R, Lo ES, Trivedi I, et al. (2012) Clostridium difficile ribotype does not predict severe infection. Clin Infect Dis 55: 1661-1668.
19. Morgan OW, Rodrigues B, Elston T, Verlander NQ, Brown DF, et al. (2008) Clinical severity of Clostridium difficile PCR ribotype 027: a case-case study. PLoS ONE 3: e1812.
20. Cloud J, Noddin L, Pressman A, Hu M, Kelly C, (2009) Clostridium difficile strain NAP-1 is not associated with severe disease in a nonepidemic setting. Clin Gastroenterol Hepatol 7: 868-873 e862.
21. Sirard S, Valiquette L, Fortier LC, (2011) Lack of association between clinical outcome of Clostridium difficile infections, strain type, and virulence-associated phenotypes. J Clin Microbiol 49: 4040-4046.
22. Wilcox MH, Shetty N, Fawley WN, Shemko M, Coen P, et al. (2012) Changing epidemiology of Clostridium difficile infection following the introduction of a national ribotyping-based surveillance scheme in England. Clin Infect Dis 55: 1056-1063.
23. Marsh JW, Arora R, Schlackman JL, Shutt KA, Curry SR, et al. (2012) Association of relapse of Clostridium difficile disease with BI/NAP1/027. J Clin Microbiol 50: 4078-4082.
24. O'Connor JR, Johnson S, Gerding DN, (2009) Clostridium difficile Infection caused by the epidemic BI/NAP1/027 strain. Gastroenterology 136: 1913-1924.
25. Akerlund T, Persson I, Unemo M, Noren T, Svenungsson B, et al. (2008) Increased sporulation rate of epidemic Clostridium difficile type 027/NAP1. J Clin Microbiol 46: 1530-1533.
26. Bourgault A-M, Lamothe F, Loo VG, Poirier L, (2006) Group C-CS (2006) In vitro susceptibility of Clostridium difficile clinical isolates from a multi-institutional outbreak in southern Quebec, Canada. Antimicrob Agents Chemother 50: 3473-3475.
27. Drudy D, Kyne L, O'Mahony R, Fanning S, (2007) gyrA mutations in fluoroquinolone-resistant Clostridium difficile PCR-027. Emerg Infect Dis 13: 504-505.
28. Drudy D, Quinn T, O'Mahony R, Kyne L, O'Gaora P, et al. (2006) High-level resistance to moxifloxacin and gatifloxacin associated with a novel mutation in gyrB in toxin-A-negative, toxin-B-positive Clostridium difficile. J Antimicrob Chemother 58: 1264-1267.
29. Merrigan M, Venugopal A, Mallozzi M, Roxas B, Viswanathan VK, et al. (2010) Human hypervirulent Clostridium difficile strains exhibit increased sporulation as well as robust toxin production. J Bacteriol 192: 4904-4911.
30. Carter GP, Douce GR, Govind R, Howarth PM, Mackin KE, et al. (2011) The anti-sigma factor TcdC modulates hypervirulence in an epidemic BI/NAP1/027 clinical isolate of Clostridium difficile. PLoS Pathog 7: e1002317.
31. Burns DA, Heeg D, Cartman ST, Minton NP, (2011) Reconsidering the sporulation characteristics of hypervirulent Clostridium difficile BI/NAP1/027. PLoS ONE 6: e24894.
32. Taylor NS, Thorne GM, Bartlett JG, (1981) Comparison of two toxins produced by Clostridium difficile. Infect Immun 34: 1036-1043.
33. Libby JM, Jortner BS, Wilkins TD, (1982) Effects of the two toxins of Clostridium difficile in antibiotic-associated cecitis in hamsters. Infect Immun 36: 822-829.
34. Lyerly DM, Phelps CJ, Toth J, Wilkins TD, (1986) Characterization of toxins A and B of Clostridium difficile with monoclonal antibodies. Infect Immun 54: 70-76.
35. Lanis JM, Barua S, Ballard JD, (2010) Variations in TcdB activity and the hypervirulence of emerging strains of Clostridium difficile. PLoS Pathog 6: e1001061.
36. Lanis JM, Hightower LD, Shen A, Ballard JD, (2012) TcdB from hypervirulent Clostridium difficile exhibits increased efficiency of autoprocessing. Mol Microbiol 84: 66-76.
37. Lyerly DM, Barroso LA, Wilkins TD, Depitre C, Corthier G, (1992) Characterization of a toxin A-negative, toxin B-positive strain of Clostridium difficile. Infect Immun 60: 4633-4639.
38. Lyras D, O'Connor JR, Howarth PM, Sambol SP, Carter GP, et al. (2009) Toxin B is essential for virulence of Clostridium difficile. Nature 458: 1176-1179.
39. von Eichel-Streiber C, Sauerborn M, (1990) Clostridium difficile toxin A carries a C-terminal repetitive structure homologous to the carbohydrate binding region of streptococcal glycosyltransferases. Gene 96: 107-113.
40. Florin I, Thelestam M, (1986) Lysosomal involvement in cellular intoxication with Clostridium difficile toxin B. Microb Pathog 1: 373-385.
41. von Eichel-Streiber C, Heringdorf DMZ, Habermann E, Sartingen S, (1995) Closing in on the toxic domain through analysis of a variant Clostridium difficile cytotoxin B. Mol Microbiol 17: 313-321.
42. Hofmann F, Busch C, Prepens U, Just I, Aktories K, (1997) Localization of the glucosyltransferase activity of Clostridium difficile toxin B to the n-terminal part of the holotoxin. J Biol Chem 272: 11074-11078.
43. von Eichel-Streiber C, Sauerborn M, Kuramitsu HK, (1992) Evidence for a modular structure of the homologous repetitive C-terminal carbohydrate-binding sites of Clostridium difficile toxins and Streptococcus mutans glucosyltransferases. J Bacteriol 174: 6707-6710.
44. Egerer M, Giesemann T, Jank T, Satchell KJF, Aktories K, (2007) Auto-catalytic cleavage of Clostridium difficile toxins A and B depends on cysteine protease activity. J Biol Chem 282: 25314-25321.
45. Jank T, Aktories K, (2008) Structure and mode of action of clostridial glucosylating toxins: the ABCD model. Trends Microbiol 16: 222-229.
46. Hammond GA, Johnson JL, (1995) The toxigenic element of Clostridium difficile strain VPI 10463. Microb Pathog 19: 203-213.
47. Stabler R, He M, Dawson L, Martin M, Valiente E, et al. (2009) Comparative genome and phenotypic analysis of Clostridium difficile 027 strains provides insight into the evolution of a hypervirulent bacterium. Genome Biol 10: R102.
48. Wren BW, (1991) A family of clostridial and streptococcal ligand-binding proteins with conserved C-terminal repeat sequences. Mol Microbiol 5: 797-803.
49. Olling A, Goy S, Hoffmann F, Tatge H, Just I, et al. (2011) The repetitive oligopeptide sequences modulate cytopathic potency but are not crucial for cellular uptake of Clostridium difficile toxin A. PLoS ONE 6: e17623.
50. Torres JF, Monath TP, (1996) Antigenicity of amino-acid sequences from Clostridium difficile toxin B. J Med Microbiol 44: 464-474.
51. Babcock GJ, Broering TJ, Hernandez HJ, Mandell RB, Donahue K, et al. (2006) Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters. Infect Immun 74: 6339-6347.
52. Steele J, Chen K, Sun X, Zhang Y, Wang H, et al. (2012) Systemic dissemination of Clostridium difficile toxins A and B is associated with severe, fatal disease in animal models. J Infect Dis 205: 384-391.
53. von Eichel-Streiber C, Laufenberg-Feldmann R, Sartingen S, Schulze J, Sauerborn M, (1992) Comparative sequence analysis of the Clostridium difficile toxins A and B. Mol Gen Genet 233: 260-268.
54. Dobson G, Hickey C, Trinder J, (2003) Clostridium difficile colitis causing toxic megacolon, severe sepsis and multiple organ dysfunction syndrome. Intensive Care Med 29: 1030.
55. Cunney RJ, Magee C, McNamara E, Smyth EG, Walshe J, (1998) Clostridium difficile colitis associated with chronic renal failure. Nephrol Dial Transplant 13: 2842-2846.
56. Sakurai T, Hajiro K, Takakuwa H, Nishi A, Aihara M, et al. (2001) Liver abscess caused by Clostridium difficile. Scand J Infect Dis 33: 69-70.
57. Stabler RA, Dawson LF, Phua LTH, Wren BW, (2008) Comparative analysis of BI/NAP1/027 hypervirulent strains reveals novel toxin B-encoding gene (tcdB) sequences. J Med Microbiol 57: 771-775.
58. Giannasca PJ, Zhang ZX, Lei WD, Boden JA, Giel MA, et al. (1999) Serum antitoxin antibodies mediate systemic and mucosal protection from Clostridium difficile disease in hamsters. Infect Immun 67: 527-538.
59. Kink JA, Williams JA, (1998) Antibodies to recombinant Clostridium difficile toxins A and B are an effective treatment and prevent relapse of C. difficile-associated disease in a hamster model of infection. Infect Immun 66: 2018-2025.
60. Kyne L, Warny M, Qamar A, Kelly CP, (2000) Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 342: 390-397.
61. Hamm EE, Voth DE, Ballard JD, (2006) Identification of Clostridium difficile toxin B cardiotoxicity using a zebrafish embryo model of intoxication. Proceedings of the National Academy of Sciences 103: 14176-14181.
62. Giannasca PJ, Zhang Z-x, Lei W-d, Boden JA, Giel MA, et al. (1999) Serum antitoxin antibodies mediate systemic and mucosal protection from Clostridium difficile disease in hamsters. Infect Immun 67: 527-538.
63. Kim PH, Iaconis JP, Rolfe RD, (1987) Immunization of adult hamsters against Clostridium difficile-associated ileocecitis and transfer of protection to infant hamsters. Infect Immun 55: 2984-2992.
64. Wang H, Sun X, Zhang Y, Li S, Chen K, et al. (2012) A chimeric toxin vaccine protects against primary and recurrent Clostridium difficile infection. Infect Immun 80: 2678-2688.
65. Grammas P, Hamdheydari L, Benaksas EJ, Mou S, Pye QN, et al. (2004) Anti-inflammatory effects of tocopherol metabolites. Biochem Biophys Res Commun 319: 1047-1052.
66. Diglio CA, Grammas P, Giacomelli F, Wiener J, (1982) Primary culture of rat cerebral microvascular endothelial cells. Isolation, growth, and characterization. Lab Invest 46: 554-563.
67. Krivan HC, Wilkins TD, (1987) Purification of Clostridium difficile toxin A by affinity chromatography on immobilized thyroglobulin. Infect Immun 55: 1873-1877.
68. Jiang W, Schwendeman SP, (2000) Formaldehyde-mediated aggregation of protein antigens: comparison of untreated and formalinized model antigens. Biotechnol Bioeng 70: 507-517.
69. Kotloff KL, Wasserman SS, Losonsky GA, Thomas W Jr, Nichols R, et al. (2001) Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults. Infect Immun 69: 988-995.
70. James JA, Harley JB, (1995) Peptide autoantigenicity of the small nuclear ribonucleoprotein C. Clin Exp Rheumatol 13: 299-305.